52 results about "Schizandrin B" patented technology

The invention relates to a Chinese magnoliavine fruit monomer composition separation preparation method; ethanol extracts from Chinese magnoliavine fruit are extracted by petroleum ether, chromatography is carried out to the petroleum ether extracts by a silicagel column, and then the petroleum ether is eluted by petroleum ether-ethylacetate, and HPLC is used for monitoring, and then crude extract A and crude extract B are fraction-collected, and eluted; the volume ratio of eluant petroleum ether and ethylacetate is 3-5:1, the crude extract A and crude extract B are respectively applied to a high-speed counter-current chromatography for separation, so as to obtain SCHisanhenol, deoxyschizandrin, schizandrin B, schisandrin C, schizandrol A, schizandrol B and schisantherrin B monomers, and the purity is higher than 98 percent.

The invention relates to a schisandra fruit fingerprint spectrum quality control method, comprising that (1), adding 0.5g schisandra fruit to extract via microwave for 50min, filtering, (2), washing flow phase gradient that the spectrum column is Eclipse, as 0-40min, 60-20% A, 40-80% B, flow speed is 0.8-1.2ml/min, the wavelength is 210-280nm, the column temperature is 20-40Deg. C, and the sample amount is 10-20ul, (3), building standard fingerprint spectrum that the first peak is schisandra fruit alcohol 1, the third peak is schisandra fruit alcohol 2, the fourth peak is gemixin N/ isomer, the sixth peak is schisandra fruit I element, the seventh and eighth peaks are gemixin N/ isomer, the ninth peak is schisandra fruit II element, (4), controlling the quality of fingerprint spectrum that the check peak relative holding times are 1.00, 1.25, 1.63, 1.88, 3.18 and 3.27, (5), the schisandra fruit planting collecting method. The invention can control the quality of materials to assure the stable quality of product.

A detection method of blood plasma schizadrin B of dissipating blood stasis botanical is disclosed. The method includes: (1) extracting schizadrin B from plasma of mammalian administered dissipating blood stasis botanical by ethyl acetate with the volume ratio 1:4, whirling 3-5 mins, centrifugating at 9600 rpm for 10 mins, drying and enriching the upper layer at 25-30° C., and redissolving with mobile phase; (2) UPLC/MS measuring: UPLC condition: chromatographic column: Acquity UPLC BEH C₁₈, 2.1′100 mm, mobile phase A: water-acetonitrile-formic acid 95:5:0.1 v/v/v, mobile phase B: acetonitrile-formic acid 100:0.1 v/v; MS condition: electric spraying ion source(ESI), detecting with positive ion mode, scanning at the range of m/z 150-1200. The method can be used for pharmacokinetics study of schizadrin B in dissipating blood stasis botanical.

The invention relates to a method for processing vinegar schisandra fruit, which can effectively prepare medicinal material of the schisandra fruit into vinegar schisandra fruit medical herb in pieces. The invention has the concrete technical scheme comprises the following steps: taking the medicinal material of the schisandra fruit, removing the non-medicinal parts such as fruit stalks, stumps and the like, adding rice vinegar, decompressing and moistening until the rice vinegar is sucked up, braising at high pressure, drying and packaging so as to obtain the vinegar schisandra fruit. The method is simple and easy to operate, the color of the prepared vinegar schisandra fruit is uniform, and the indexes of the contents of water content, ash content and the like are all within a range specified by a dispensatory; compared with a normal-pressure vinegar braising product of the vinegar schisandra fruit, no obvious difference exists in the contents of general lignanoid, schisandrol A, schisandra fruit essence B and general organic acid; compared with the normal-pressure vinegar braising product, the contents of 5-hydroxymethyl furfural and general polysaccharide are higher; and compared with a traditional normal-pressure braising process, the processing method adopting high-pressure vinegar braising lowers energy consumption and saves time. Therefore, the invention can be popularized and used for large-scale production, provides concrete technical data for the processing of the vinegar schisandra fruit and provides ground for the execution of the standardized production operation rule of traditional Chinese medicine medical herb in pieces.

The invention provides a method for measuring the content of a Shenqi blood sugar reducing preparation. The method is used for measuring the content of 10 active ingredients in the Shenqi blood sugar reducing preparation: ginsenoside Rb1, ginsenoside Rc, ginsenoside Rd, ginsenoside Rg1, ginsenoside Re, astragaloside, deoxyschizandrin, schisandrol A, schisandrol B. In the invention, with the guidance of blood sugar reducing activity of a compound, multiple active substances in the compound are detected, and the quality level of the whole compound preparation can be reflected better; meanwhile, a Q-MS ion monitoring mode is selected for content measurement, and the mass spectrum quantification has high accuracy, specificity and sensitivity and is superior to traditional HPLC analysis method; and moreover, fingerprint is established according to the liquid phase diagrams of different batches of Shenqi blood sugar reducing preparations obtained by the method, the similarity is evaluated, the inherent quality of the Shenqi blood sugar reducing preparation product is evaluated more scientifically and comprehensively, and a basis is provided for establishing a quality standard of higher level.

The invention provides a preparation method of liver protection tablets. The liver protection tablets are prepared from the raw material medicines of 250g of radix bupleuri, 250g of herba artemisiae scopariae, 250g of radix isatidis, 300g of fructus schisandrae chinensis, 20g of pig bile powder and 128g of mung bean by microwave extraction. Through the invention, the content of schisandrin b is greatly increased.

This invention relates to a method of preparing high-purity Schisandrin B. The invention adopts analysis mode high speed counter-current chromatography to proceed small scale preparation, adopt semipreparative type high speed counter-current chromatography to proceed large-scale preparation. The feature is that in solvent system the volume ratio of normal hexane, methanol, water and acetonitrile is 5 - 11 : 3 - 6 : 2 - 5 : 1, and the best volume ratio is 10:5:4:3. The invention does not need solid padding, has no irreversible adsorption and no pollution.The purity of gained Schisandrin B can reach 98%upwards.

The present invention provides a method of potentiating radiation therapy for treatment of a cancer or tumor comprising administrating to a subject in need thereof a therapeutically effective amount of a radiosensitizer in combination of a radiation therapy to a locus of the cancer or tumor, wherein the radiosensitizer is an extract of Schisandra chinensis (Turcz.) Baill, or the active ingredient isolated therefrom, particularly Schisandrin B.

The invention discloses a Chinese magnoliavine fruit lignan single component preparation, and belongs to the technical field of medicines, and especially, by addition of a surfactant into a lipophilic Chinese magnoliavine fruit lignan extract for formation of a uniform aqueous solution, macroporous adsorption resin can be effectively used for preliminary purification, subsequent chromatographic purification operation load can be reduced, then ODS-A-HG or ODS-A reversed-phase C18 packing is used for chromatographic purification, and an ethanol aqueous solution is used for gradient elution to obtain schizandrin a, schizandrin b, schisantherin a, schisantherin b, deoxyschizandrin, and schisandrin b single components with the purity of more than 98%. The method has the advantages of being simple in operation, non-pollution, low in cost, less in time consuming, high in yield, easy to enlarge in industry, and the like.

The invention discloses a medical composite for preventing and curing Alzheimer's disease (AD). The composite comprises the following raw materials in parts by weight: 10-40 parts of hyperin, 20-80 parts of icariin and 5-20 parts of Schisandrin B. Experiments of rat place navigation and space exploration prove that the medical composite of the invention can increase the ability of spatial learning and memory of AD rat model, namely reduce the escape latency and scouting distance and obviously increase the percent of scouting time in quadrant of original platform to total time and the percent of scouting distance in quadrant of original platform to total distance in space exploration experiments. Therefore, the extract composite can be used for preventing and curing AD.

The invention belongs to the field of traditional Chinese medicines or the pharmaceutical chemistry, and relates to a medicinal composition for resisting hepatic fibrosis and/or hepatic cirrhosis. The medicinal composition includes ursolic acid and schisandrin B. The invention also relates to a use of the medicinal composition in the preparation of medicines for treating and/or preventing and/or adjunctively treating hepatic fibrosis and hepatic cirrhosis, or medicines for inhibiting hepatic stellate cell proliferation or inhibiting hepatic stellate cell DNA synthesis, and a method for inhibiting hepatic stellate cell proliferation or inhibiting hepatic stellate cell DNA synthesis. The medicinal composition can obviously improve the hepatic fibrosis degree, has the advantages of few components, strong effect, simple preparation, no obvious hepatotoxicity, and good market prospect, and is of certain practical significance for promoting traditional Chinese medicinal modernization.

The invention provides an application of schisandrin b in preparing an NADPH oxidase inhibitor. The NADPH oxidase comprises various sub-types of oxidase. In in-vitro enzymatic experiments, the schisandrin b is capable of inhibiting super-oxygen ion generation reaction catalyzed by NADPH oxidase and reactive oxygen generation related to NADPH oxidase in cells, and does not have the function of scavenging free radicals, thus being an inhibitor of the NADPH oxidase. Furthermore, the NADPH oxidase is capable of changing the level of a plurality of signal transduction pathways and inhibiting generation of tumor metastasis, and can be applied to preparation of medicaments for treating tumor metastasis.

The invention discloses a preparing method of biphenyl cyclo-octadiene lignans and application in the tumour prevention drug, which is characterized by the following: reducing cardiovascular toxicant or liver toxicant or kidney toxicant or marrow inhibition or immune inhibition or alopecia, adopting schizandrin to lessen side-effect of tumour prevention drug effectively.

The invention discloses a compound plant growth regulator containing a brassinolide compound, and relates to the technical field of plant growth regulators. The compound plant growth regulator disclosed by the invention comprises active components and a synergist, wherein the active components comprises a brassinolide compound and one or two selected from (+)-abscisic acid and indolebutyric acid,and the synergist comprises schisandrin B, alisol B acetate and an alcohol solution of alkannin. The compound plant growth regulator not only has an obvious synergistic effect, but also can improve the germination rate, promote growth of plant roots and crowns, further improve quality of crops and improve the yield of the crops. The schisandrin B, the alisol B acetate and the alkannin are preparedinto the synergist to be matched with the active components for use, so that nutrient substances required by plants are provided, quality of crops is improved, growth of the crops is promoted, and the effect of increasing production and income is achieved.

The invention discloses an application of schisandrin B in preparation of a diabetes treatment drug and provides pharmaceutical composition taking the schisandrin B as the effective component. The pharmaceutical composition can effectively reduce the blood glucose level of a diabetic patient, and the effective action concentration is far lower than metformin which is a first-line drug in the market.

The invention relates to an endophytic fungi for improving content of main active ingredients of schisandra chinensis through a fermentation method. The endophytic fungi is Aspergilluspenicillioides WT4 which is preserved in the China Center for Type Culture Collection (CCTCC) with preservation numbers of CCTCC No: M2012043 in Wuhan University in Wuhan city, and the preservation date is February 29, 2012. The WT4 in the endophytic fungi can remarkably improve the main active ingredients of the schisandra chinensis, such as schizandrin, schisantherin, deoxyschizandrin and schisandrin b. Therefore, in the raw material production with the purpose of obtaining the schizandrin, the schisantherin, the deoxyschizandrin and the schisandrin b, people can select schisandra chinensis endophytic fungi WT4 to ferment the schisandra chinensis to improve the yield and save medicinal resources.

The invention discloses three Chinese magnoliavine fruit extracts as well as a preparation process and application thereof, and belongs to the technical field of medicines. The preparation method of the Chinese magnoliavine fruit extract comprises the following steps: treating Chinese magnoliavine fruit by using a CSFE method to obtain an extract A, and placing the extract at room temperature for layering to obtain an extract B (rich in schisandrin B) and an extract C (rich in schizandrin); boiling the decoction dregs, adding beta-cyclodextrin into filtrate to carry out inclusion adsorption on residual fat-soluble active ingredients in the decoction dregs, and filtering to obtain the inclusion adsorption lignan; performing concentration and alcohol precipitation on the filtrate to obtain the Chinese magnoliavine fruit polysaccharide; respectively combining the inclusion adsorption lignan and polysaccharide with the extracts A, B and C to obtain an extract I, an extract II and an extract III. The content of effective parts of the three extracts accounts for more than 50% of the extracts, the three extracts are composed of three active components including total lignan, linoleic acid and polysaccharide, and the total lignan is 18-25%. Different new drugs can be developed from the three extracts according to different proportions of schisandrin B and schizandrin for resisting depression, promoting sleep, promoting intelligence and other indications.

The invention discloses a novel natural herbal compound composition with sobering and liver protecting effects and preparation as well as application thereof. The composition is prepared from active ingredients which mainly have the sobering and liver protecting effects and auxiliary materials, wherein the composition of the active ingredients comprise the following components in percentage by weight based on total weight of the active ingredients: 3-10 percent of sesamin, 0.05-5 percent of schisandrin, 10-45 percent of hovenia dulcis thumb extract, 10-45 percent of kudzu vine flower extract, 10-45 percent of nutgrass galingale rhizome extract, 0-0.02 percent of vitamin B12 and 1-10 percent of vitamin E acetate. The invention also relates to application of the composition to preparation of health care foods for preventing and/or treating acute alcoholism, health care foods for treating chronic alcoholic liver damage and health care foods for treating nonalcoholic fatty liver. The composition has the advantages of good synergistic reaction among the components, obvious curative effect, readily available raw materials, easiness in preparation and relatively low cost.

The invention discloses a health care product for preventing and treating a chemical liver injury. The health care product is prepared with schisandrin b and procyanidine as main raw materials, and the health care product has the exact curative effect on the chemical liver injury.

The invention discloses application of schisandrin B in preparation of drugs for treatment of diabetic complications. Specifically, schisandrin B reaches the effect of treatment of diabetic complications through targeted inhibition of myeloid differentiation factor 88 (MyD88) to generate the action mechanism of lowering chronic inflammation. The schisandrin B is superior to oral administration (used for preparation of powder, tablets, pills, oral liquid and capsules). Schisandrin B can effectively relieve the occurrence and development of diabetic cardiomyopathy and diabetic nephropathy, and can become a main component in drugs for treatment of diabetic complications.

The invention discloses application of schisandrin B in preparation of drugs used for preventing colitis or colorectal carcinomas. The usage amount of schisandrin B is 15 to 30 mg per kg of body weight. Schisandrin B can effectively prevent colitis and colorectal carcinomas related to colitis, so schisandrin B has clinical application prospect; schisandrin B has low toxicity and small side-effect, can reduce generation of inflammatory factors and has good druggability; thus, schisandrin B has good application prospects in clinical prevention and treatment.

The invention discloses schisandra chinensis dl-tetrahydropalmatine preparation. Main raw materials of the preparation are schisandra chinensis dl-tetrahydropalmatine and granulesten. The preparation has exact curative effect on chemical liver injury.

The invention provides a schisandrinB solid dispersion and a preparation method thereof as well as a medical preparation containing the solid dispersion. The schisandrinB solid dispersion is prepared from main raw materials including schisandrinB and povidone at the weight ratio of 1:(2-8) by a solvent method or a grinding method. The results of vitro dissolution, DSC and XRD examination and stability test of the obtained schisandrinB solid dispersion and the preparation thereof show that the prepared solid dispersion of the schisandrinB, disclosed by the invention, exists in an amorphism state or a molecular state, the vitro dissolution is greatly improved, the prepared preparation is stable, and the oral bioavailability of the schisandrinB is improved.